Advertisement
Following the signature of an EPFL-Debiopharm partnership on February 12,this first joint research project will be performed under the supervision ofDr. Freddy Radtke, Associate Professor at the Swiss Institute forExperimental Cancer Research (ISREC) and Dr. Gerardo Turcatti, MER, Directorof the Biomolecular Screening Facility (BSF), two groups at the EPFL. Debio0826 will benefit from the multiple molecular and genetic tools generated byDr. Radtke's group over the past 10 years, as well as the expertise of Dr.Turcatti in the molecular screening field.
Advertisement
"Targeting pathways controlling cell fate specification could generateinnovative anti-cancer drugs with anti-tumoural, anti-metastatic andanti-angiogenic properties to treat tumours that are currently resistant tostandard therapies," said Kamel Besseghir, CEO of Debiopharm S.A.
About Debiopharm Group
Debiopharm Group is a global biopharmaceutical development specialistthat in-licenses promising biologics and small molecule drug candidates.Debiopharm develops its products for global registration and maximumcommercial potential for out-licensing to pharmaceutical partners for salesand marketing. Debiopharm independently funds the worldwide development ofall of its products while providing expertise in pre-clinical and clinicaltrials, manufacturing, drug delivery and formulation, and regulatory affairs.
Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharmhas developed three products with global combined sales in excess of $2.65billion in 2007.For more information on Debiopharm Group, please visit:http://www.debiopharm.com. Debiopharm S.A. Contacts Andres McAllister Chief Scientific Officer Tel.: +41(0)21-321-01-11 Fax: +41(0)21-321-01-69 [email protected] Additional Media Contacts In London Maitland Brian Hudspith Tel: +44(0)20-7379-5151 [email protected] In New York Russo Partners, LLC Wendy Lau Tel: +1-212-845-4272 Fax: +1-212-845-4260 [email protected]
SOURCE Debiopharm Group
